US Patent

US8653137 — Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same

Method of Use · Assigned to United Therapeutics Corp · Expires 2028-09-05 · 2y remaining

Vulnerability score 83/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects buffer solutions with specific pH levels that have bactericidal activity against gram-negative bacteria, and methods of using them to reduce blood stream infections in mammals.

USPTO Abstract

Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1437 — Remodulin
U-1437 — Remodulin
U-1437 — Remodulin
U-1437 — Remodulin
U-1437 — Remodulin
U-1437 — Remodulin
U-1437 — Remodulin
U-1437 — Remodulin

Patent Metadata

Patent number
US8653137
Jurisdiction
US
Classification
Method of Use
Expires
2028-09-05
Drug substance claim
No
Drug product claim
No
Assignee
United Therapeutics Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.